|1.||Alitalo, Kari: 34 articles (06/2015 - 03/2002)|
|2.||Pytowski, Bronislaw: 15 articles (03/2014 - 08/2004)|
|3.||Ylä-Herttuala, Seppo: 9 articles (06/2015 - 10/2003)|
|4.||Stacker, Steven A: 9 articles (08/2013 - 06/2002)|
|5.||Achen, Marc G: 9 articles (08/2013 - 06/2002)|
|6.||Detmar, Michael: 8 articles (02/2015 - 12/2006)|
|7.||Bremnes, Roy M: 8 articles (01/2015 - 11/2007)|
|8.||Donnem, Tom: 8 articles (01/2015 - 11/2007)|
|9.||Busund, Lill-Tove: 8 articles (01/2015 - 11/2007)|
|10.||Cance, William G: 8 articles (01/2015 - 02/2006)|
03/01/2006 - "In adjuvant immunofluorescence studies, the CD31-positive endothelial cells of microvessels showed decreased VEGFR-3 expression in IL-12-treated tumors. "
04/01/2015 - "Tumor VEGFR-3 and PDGFRα expression appeared to confer a divergent prognostic effect. "
06/15/2014 - "Vascular endothelial growth factor receptor 3 (VEGFR-3) supports tumor lymphangiogenesis. "
01/01/2014 - "Specificity of in vivo effects for C4 were confirmed by a decrease in tumor FAK and VEGFR-3 phosphorylation, reduction of vasculogenesis and reduced blood flow. "
01/01/2014 - "The new invasion and stem cell markers VEGFR-3 and CXCR4 have been linked prognostically with more aggressive esophagogastric cancer types. "
|2.||Neoplasm Metastasis (Metastasis)
06/25/2006 - "These findings have prompted studies to investigate whether inhibitors of VEGFR-3 activation might represent novel therapeutic agents for the suppression of metastasis. "
12/01/2014 - "VEGFR-3 and Hif1α were associated with lymph node metastases and T stage. "
01/01/2014 - "In patients without lymph node metastasis at the time of RC, an assessment of VEGFR-3 expression may improve the identification of high-risk patients. "
01/01/2014 - "In a subgroup of patients without lymph node metastasis (pN0; n = 75), pT stage (P = 0.043) and VEGFR-3 overexpression (P = 0.008) were independent predictors of reduced DSS. "
08/01/2013 - "Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis."
11/15/2008 - "In this study, we examined the expression and function of VEGFR-3 in gastric carcinoma cells. "
04/01/2008 - "The purpose of this study was to investigate the expression of VEGFR-3 and its clinicopathological significance in primary gastric carcinoma (GC). "
01/01/2011 - "Overexpression of VEGFR-3 reflects the aggressiveness of ovarian carcinoma spread and has a predictive value for identifying high-risk patients with poor prognosis."
04/22/2009 - "Similarly, ligand-induced autophosphorylation of these RTKs in human vulva carcinoma or porcine aortic endothelial cells was suppressed by both mixtures, with ErbB3 and VEGFR-3 being preferentially inhibited. "
11/15/2008 - "We examined the expression of VEGFR-3 by four human gastric carcinoma cell lines and in 36 surgical specimens of gastric carcinoma. "
|4.||Breast Neoplasms (Breast Cancer)
12/01/2013 - "VEGFR-3 was expressed in 55.5% (96/173) breast cancer patients of experimental group, while the expression was negative in lesions of control group. "
12/01/2013 - "To investigate the expression and prognostic value of vascular endothelial growth factor receptor 3 (VEGFR-3) in human breast cancer. "
12/01/2013 - "[Expression of vascular endothelial growth factor receptor 3 in human breast cancer and its significance]."
07/15/2009 - "For the first time, we have demonstrated that VEGFR-3 overexpression promotes breast cancer cell proliferation, motility, survival, anchorage-independent growth and tumorogenicity in the absence of ligand expression."
07/15/2009 - "We characterized the biological effects of VEGFR-3 over-expression in human breast cancer cells based on two approaches: gain of function by overexpressing VEGFR-3 in MCF-7 breast cancer cells and loss of function by RNAi-mediated silencing of VEGFR-3 in MCF-7-VEGFR-3 and BT474 cells. "
|5.||Lung Neoplasms (Lung Cancer)
08/20/2004 - "In human kidney, breast, colon, gastric and lung cancer tissues the protein levels of VEGFR-3 were in the range of 0.6-16.7 ng/mg protein. "
01/01/2006 - "The results showed that VEGF-C and VEGFR-3 were highly expressed in cytoplasm and membrane in lung cancer tissues with the positive rate being 55.4 % and 52.3 % respectively, while there was no expression in the normal lung tissues. "
05/01/2003 - "In NSCLC, VEGF-C and VEGFR-3 are related to the lymphangiogenesis, angiogenesis, and occurrence and development of lung cancers. "
01/01/2006 - "The interaction between VEGF-C and VEGFR-3 may be deeply involved in the mechanism of lung cancer metastasis."
06/15/2014 - "Our previous studies show that activation of the VEGF-C/VEGFR-3 axis promotes cancer metastasis and is associated with clinical progression in patients with lung cancer, indicating that VEGFR-3 is a potential target for cancer therapy. "
|1.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|2.||Vascular Endothelial Growth Factor C
|3.||Vascular Endothelial Growth Factor D
|5.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Vascular Endothelial Growth Factors
|10.||Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|5.||Homologous Transplantation (Allograft)